New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
09:37 EDTAMGN, GSKAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Amgen (AMGN) disclosed in a regulatory filing that the company and Glaxo Group (GSK) entered into an agreement terminating in part and amending in part the collaboration agreement dated as of July 27, 2009 relating to the commercialization of denosumab for osteoporosis indications in certain geographic territories. The transition agreement terminates the prior collaboration agreement for all countries and regions of the collaboration territory, including the European Union, Switzerland, Norway, Russia and Mexico, except for Australia. All commercial activities assigned to GSK under the collaboration agreement other than those in Australia will be transitioned back to Amgen no later than December 31. In exchange for the early termination, except Australia, Amgen will pay to GSK an initial payment and specific milestones over the transition period totaling $275M. In addition, Amgen will reimburse GSK $15M for costs incurred by GSK in performing its obligations. The transition agreement does not change the terms of the separate expansion agreement dated as of July 27, 2009 relating to the commercialization of denosumab for all indications in certain geographic territories, Amgen said.
News For AMGN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
16:39 EDTGSKCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
08:01 EDTGSKGE Healthcare to collaborate with GlaxoSmithKline in commercial oncology testing
GE Healthcare (GE) announced an agreement between its affiliate, Clarient Diagnostic Services, and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration will enable GE to develop a broader laboratory and data analytics service that will enable better efficiency in the healthcare market related to oncology precision medicine. This will be made available as a subscription-based service and operated by GE Healthcare. Under terms of the agreement with GSK, GE Healthcare, through its Clarient affiliate, will initially use its clinical laboratory, pathology and genomics expertise, to certify laboratories and generate diagnostic data on metastatic melanoma patients. The first Clarient certified laboratories to initiate this work, are expected to be operational in several countries in early 2015. Laboratory testing will initially focus on more than 70 mutations relevant to melanoma, including BRAF V600E and V600K, with the opportunity to expand testing beyond melanoma into other tumor types, as the network of clinical laboratories develops.
07:30 EDTGSK, AMGNSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
13:47 EDTGSKGlaxoSmithKline reports 45% survival rate of Tafinlar-treated melanoma patients
Subscribe for More Information
07:26 EDTAMGN, GSKInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
05:36 EDTGSKGlaxoSmithKline names Philip Hampton Non-Executive Director
Subscribe for More Information
September 24, 2014
10:18 EDTGSKGlaxoSmithKline set to name RBS' Philip Hampton as next chairman, Sky News says
Subscribe for More Information
September 23, 2014
08:29 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
08:07 EDTGSKFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
10:15 EDTGSKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
07:21 EDTGSKEBD Group to hold a conference
Subscribe for More Information
05:27 EDTGSKGlaxoSmithKline upgraded to Buy from Neutral at Goldman
Subscribe for More Information
September 19, 2014
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use